Other languages Johnson & Johnson Kazakhstan S.E.

Equities

JNJ_KZ

US4781601046

End-of-day quote Kazakhstan S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
146.8 ^USD	+1.23%		-1.46%	-6.74%

02:36am	J&J must pay $260 million in latest talc trial, Oregon jury says	RE
03/06	Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Borsa di Italia: Mai contenti!	11:30am
J&J must pay $260 million in latest talc trial, Oregon jury says	06:06am
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	04/06
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	04/06
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	03/06
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	03/06
GSK blood cancer drug nearly halves risk of death in late-stage trial	02/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
Johnson & Johnson Announces First Data from the Phase 3 PALOMA-3 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib	01/06
Sector Update: Health Care Stocks Higher Late Afternoon	01/06
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	01/06
Sector Update: Health Care Stocks Advance Friday Afternoon	31/05
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	31/05
J&J : finalise l'acquisition de Shockwave Medical	31/05
Johnson & Johnson Closes Acquisition of Shockwave Medical	31/05
Johnson & Johnson completed the acquisition of Shockwave Medical, Inc. from a group of sellers.	31/05
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	30/05
J&J : résultats encourageants dans le soin de la dépression	29/05
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	29/05
J&J's treatment for depression succeeds in late stage study	29/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST